# Vinorelbine and Gemcitabine in Myeloma

> **NCT02791373** · PHASE2 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 136 (actual)

## Conditions studied

- Multiple Myeloma
- Amyloidosis

## Interventions

- **DRUG:** Vinorelbine
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02791373
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2017-12-31
- **Final completion:** 2017-12-31
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2018-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02791373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02791373, "Vinorelbine and Gemcitabine in Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02791373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*